Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Presentation on co drug strategy for treating hypertension in type ii


Published on

This presentation is on co-drug design, two drugs are chemically linked together for their improved delivery properties so as to reach a site simultaneously achieving better absorption as compared to when co-administered in separate dosage forms.

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Presentation on co drug strategy for treating hypertension in type ii

  1. 1. CO-DRUG STRATEGY FOR TREATING HYPERTENSION IN TYPE- II DIABETES Presented by: Guided by: Latika Budhalakoti Dr. Suneela Dhaneshwar M.Pharm (Pharm chem.) Professor Department of Pharmaceutical Chemistry Poona College of Pharmacy Bharati Vidyapeeth Deemed University Erandwane, Pune -411 038 1
  2. 2. CONTENTS • Introduction • Drug therapies • Disadvantages and advantages of co- drug therapy. • Drugs profile • References 2
  3. 3. Diabetes mellitus (DM) • DM is a chronic metabolic disorder characterised by a high blood glucose concentration. 1 • Preprandial plasma glucose (before a meal)-70–130 mg/dl . • Postprandial plasma glucose (after a meal) – 120- 160 mg/dl. 2hr after a meal.  TYPE-I DIABETES: Insulin deficiency. Insulin dependent diabetes mellitus(10%)  TYPE-II DIABETES: Insulin resistance. Non-insulin dependent diabetes mellitus.(90%) 1 Pathophysiology of Diabetes Mellitus3
  4. 4. Drug therapy 2 Insulin secretogogues: ● Sulfonyl ureas:  First generation: Tolbutamide,Tolazamide  Second generation: Glimepiride,gliclazide ● Meglitinides: Repaglinides,Nateglinides Tolbutamide Gliclazide Repaglinide 4
  5. 5.  Biguanides: Metformin  Insulin sensitizers:  2,4-Thiazolidine diones: Pioglitazone,Rosiglitazone  Glycogen like peptide-1 analogues(GLP-1): Exenatide,Liraglutide Pioglitazone Liraglutide Metformin 5
  6. 6. 6
  7. 7. Drawbacks of the current therapies 1 7
  8. 8. Hypertensive diabetes • Hypertension is an extremely common co-morbidity of diabetes, affecting 20–60% of diabetics depending on age, ethnicity and obesity. • In type II diabetes, hypertension is often present as part of the metabolic syndrome of insulin resistance also including central obesity and dyslipidemia. • The prevalence of hypertension in the diabetic population is 1.5–3 times higher than that of non- diabetic groups. 8
  9. 9. Pathogenic mechanisms of hypertension in type II diabetes 7 ● Sympathetic nervous system activation. ● Abnormal ion transport. ● Renin–angiotensin–aldosterone system activation. ● Endothelial dysfunction altering vascular tone. 9
  10. 10. • Hypertension substantially increases the risk of cardiovascular complications twice in diabetics than nondiabetics. • The macrovascular and microvascular complications include stroke, coronary artery disease, and peripheral vascular disease, retinopathy, nephropathy, and possibly neuropathy. • Cardiovascular disease is the most costly complication of diabetes and is the cause of 86% of deaths in diabetics. Cardiovascular complications of diabetics 10
  11. 11. Proportion of diabetic complications attributable to high blood pressure 6,7 Complication Proportion attributable to hypertension%  Stroke  Coronary artery disease  End-stage renal disease  Eye disease  Leg amputation  75 %  35 %  50 %  35 %  35 % 11
  12. 12. • Diabetic patients with blood pressures >130 mmHg systolic or >80 mmHg diastolic are candidates for antihypertensive treatment aimed at lowering blood pressure to <130/80 mmHg. • Well-designed randomized clinical trials have demonstrated the effectiveness of aggressive antihypertensive treatment in reducing diabetes complications. • In the U.K. Prospective Diabetes Study (UKPDS), each 10- mmHg decrease in mean systolic blood pressure was associated with reductions in risk of 12% for any complication related to diabetes, 15% for deaths related to diabetes, 11% for myocardial infarction, and 13% for microvascular complications. 12
  13. 13. Hypertension in diabetes  The association of arterial hypertension and diabetes mellitus is frequent.  The majority of people with diabetes have hypertension and 17% of those with hypertension (blood pressure 140/90 mmHg or greater, or on treatment) have been diagnosed with diabetes. 8  Excess hypertension frequency is marked in type II, non insulin-dependent diabetes.2  Treatment of high blood pressure in people with diabetes results in large reductions in death, disability and reduces overall health cost. 13
  14. 14. Drug treatment in hypertensive patients with type II diabetes 2 14 Ca2+ channel blockers Nifidipine Diuretic Hydrochlothiazide
  15. 15. ACE inhibitors: First line treatment for hypertensive diabetes  Benefits of ACE inhibitors as the first-line agents for treating macrovascular and microvascular complications in hypertensive diabetes:  Cardioprotective benefits.  Specific renoprotective actions.  Delayed progression of microalbuminuria to overt nephropathy.  Retarded deterioration of established renal impairment.  Positive impact on glucose metabolism. 15
  16. 16. Disadvantages of combination therapy  Frequent dosing in a day.  Non compliance  Increased cost  When two drugs are co-administered in separate dosage forms or in a multicomponent formulation, their ADME is independent of each other. 16
  17. 17. Advantages of co- drug therapy ● In co-drug design, two drugs are chemically linked together for their improved delivery properties so as to reach a site simultaneously achieving better absorption as compared to when co-administered in separate dosage forms.  Extended release possible by selection of appropriate linkage.  Both drugs available at the activation site.  Improved patient compliance.  Cost effective.  ADME fate of both the drugs is same till the prodrug gets activated. 17
  18. 18. Drug profile CAPTOPRIL • IUPAC name: 1-[(2S)-2-methyl-3-sulfanylpropanoyl] pyrrolidine-2-carboxylic acid • Chemical formula: C9H15NO3S • Molecular weight : 217.2853 g/mol • Melting point : 160 °C • Log P : 0.272 (n-octanol: water) • Aqueous solubility : 160 mg/ml • Bioavailability: 70–75% • Half life: 1.9 h • Metabolism: Hepatic • Excretion: Renal • Protein binding : 25-30% • Route: Oral. • Dose: 25-150 mg b.i.d or t.i.d 18
  19. 19. Captopril  First ACE inhibitor developed (1978).  Blocks the convertion of Ang - I to Ang -II by inhibiting ACE.  Indicated in diabetic nephropathy in patients with type 2 non insulin-dependent diabetes mellitus.  It decreases the rate of progression of renal insufficieny. ● Other indications- Hypertensive crises, reno-vascular hypertension, chronic kidney diseases, stroke prevention.  It shows positive impact on glucose metabolism in hypertensive diabetes. ● Side effects: Persistent cough, urticaria and taste disturbance. 19
  20. 20. Drug profile • IUPAC name: N,N-dimethylimidodicarbonimidic diamide • Chemical formula: C4H11N5 • Molecular weight : 129.163 g/mol • Melting point : 223- 226 °C • Log P : - 1.43 (n-octanol: water) • Aqueous solubility : 1.38 g/l • Bioavailability: 50-60% • Half life: 6.2 h • Metabolism: Not metabolized • Excretion: Renal • Protein binding : Negligible • Route: Oral. • Dose: 500 mg b.i.d . METFORMIN•Alkyl substitution at N 1 increases activity through n-pentyl, but decreases with longer chain length, branching, or with cyclic alkyl substituents. 1 20
  21. 21. Metformin  Lowers blood glucose, increases glucose uptake and utilisation in muscle , reduces hepatic glucose production (gluconeogenesis).  Drug of choice for non-insulin dependent diabetes mellitus patients. ● Indications: Type II DM, obese patients and those who fail to respond to treatment with diet alone. It does not cause hypoglycemia. ● Side effects:  GIT disturbances (anorexia, weight loss, diarrhea) transient, lactic acidosis rare but potencially fatal.  Metformin should be avoided in patients who predispose to lactic acidosis (renal and hepatic disease, heart failure).  Excess hypertension frequency is marked in type II, non insulin- dependent diabetes. 21
  22. 22. References 1 Lippincott Illustrated Review Pharmacology; Pamela, C. C.; Richard, A. H.; Eds 4th.; Lippincott Williams & Wilkins, a Wolters Kluwer business: USA, 2009; pp 352-354. 2 Foye’s Principles of Medicinal Chemistry; Lemke, T. L.; Williams, D. A.; Roche, V. F.; Zito, S. W.; Eds 6th.; Lippincott Williams & Wilkins, a Wolters Kluwer business: USA, 2008; pp 738-768 . 3 Huttunen, K.M.; The First Bioreversible Prodrug of Metformin with Improved Lipophilicity and Enhanced Intestinal Absorption. J. Med. Chem. 2009, 52( 14), 4142–4148. 4 Thomas M. D.; Metformin – Cysteine Prodrug. US Patent Pub lication. 2011, US 2011/0257432. 22
  23. 23. References 5 Bild, D.; Teutsch, S.M. The control of hypertension in persons with diabetes. A public health approach. Public Health. 1987;102:522-529. 6 Hypertension in diabetes: A call to action, NRC Campbell Leiter, L.A.; Larochelle, P.; et al. Hypertension in diabetes. A call to action, , NRC Campbell . 2009, 25(5), 299-302. 7 Steven, J. H.; Patrick, M. B. Diabetes and hypertension. MEDICINE, Elsevier Ltd, 34, (2), 2006, 76. 8 Canadian Diabetes Association clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008, 32, S1-S201. 23